Genetic Technologies Limited · ASX:GTG
Genetic Technologies — Shareholder Meeting (November 2022)
39 slides from Genetic Technologies's shareholder meeting presentation, Nov 28, 2022
Slide 1: Annual General Meeting
Annual General Meeting November 28, 2022 Authorised by the Board of Directors of Genetic Technologies Limited ASX: GTG NASDAQ: GENE
Slide 2: Agenda
Agenda • Chairman’s address – Mr Peter Rubinstein • Business of the Meeting • 2022 Annual Report and auditors’ report • Resolutions 1. Remuneration report 2. Re-elect Mr Nick Burrows 3. Increased placement capacity 4. Amendment to the Constitution • CEO address – Mr Simon Morriss • Q&A
Slide 3: Questions
Questions To ask a written question, select the “Q&A’ icon and select the topic your question relates to Type the question into the chat box at the bottom of the screen and press “Send” Your question will be sent immediately for review Received To ask a verbal question follow the instructions below
Slide 4: Voting Instructions
Voting Instructions When the poll is open, select the “Vote” icon and voting options will appear on your screen To vote simply select the direction in which you would like to cast your vote. A tick will appear to confirm receipt of your vote For Against Abstain To change or cancel your vote, select
Slide 5: Chairman's Address
Chairman's Address Mr. Peter Rubinstein
Slide 6: Items of business
Items of business First item of business: to receive and consider the financial statements and reports for the year ended 30 June 2022
Slide 7: Resolution 1: Adoption of the Remuneration Report
Resolution 1: Adoption of the Remuneration Report “That for the purpose of Section 250R(2) of the Corporations Act and all other purposes the Remuneration Report as set out in the Directors’ report for the Company for the year ended 30 June 2022 be adopted.”
Slide 8: Resolution 1: Adoption of the Remuneration Report
Resolution 1: Adoption of the Remuneration Report • Proxy Voting: Vote type Voted % For 541,123,404 83.3% Against 101,153,924 15.6% Open-Usable 7,467,502 1.1% Abstain 85,254,478
Slide 9: Resolution 2: Re-Election of Mr Nick Burrows
Resolution 2: Re-Election of Mr Nick Burrows “To elect Mr Nick Burrows who retires by rotation in accordance with clause 20.3 of the Company’s Constitution and being eligible offers himself for re-election as a Director.”
Slide 10: Resolution 2: Re-Election of Mr Nick Burrows
Resolution 2: Re-Election of Mr Nick Burrows • Proxy Voting: Vote type Voted % For 739,948,815 86.7% Against 105,946,465 12.4% Open-Usable 7,977,502 0.9% Abstain 83,645,835
Slide 11: Resolution 3: Approval of increased placement capacity
Resolution 3: Approval of increased placement capacity “That pursuant to and in accordance with Listing Rule 7.1A and for all other purposes, Shareholders approve the increase in capacity of the Company to issue of Equity Securities up to 10% of the issued capital of the Company (at the time of the
Slide 12: Resolution 3: Approval of increased placement capacity
Resolution 3: Approval of increased placement capacity • Proxy Voting: Vote type Voted % For 783,009,659 83.8% Against 142,988,184 15.3% Open-Usable 7,967,502 0.9% Abstain 3,553,272
Slide 13: Resolution 4: Amendment to the Constitution
Resolution 4: Amendment to the Constitution “That for the purposes of section 136(2) of the Corporations Act, the existing constitution of the Company be amended as detailed in the Explanatory Memorandum, effective at the close of this meeting.”
Slide 14: Resolution 4: Amendment to the Constitution
Resolution 4: Amendment to the Constitution • Proxy Voting: Vote type Voted % For 696,223,379 83.8% Against 126,326,114 15.2% Open-Usable 8,074,645 1.0% Abstain 106,894,479
Slide 15: Chief Executive Officer Address
Chief Executive Officer Address Mr. Simon Morriss The Future: Unlocking personalised preventative medicine
Slide 16: World leading portfolio
World leading portfolio Most comprehensive guideline driven portfolio for human and animal health. • Patented GeneType Multi Risk Test • Non-Invasive Prenatal Testing (NIPT) • Carrier screen testing • Pharmacogenomics • Oncogenetic diseases • Pet care Revenues anchored by our 3 brands to seize a mul
Slide 17: Patented Genetype tests
Patented* Genetype tests Integrate polygenic risk and clinical risks for critical medical conditions Genetype tests integrate individual’s familial, clinical and genetic information to actionable clinical insights. A non-invasive saliva based test combines genetic and clinical risk models with cutti
Slide 18: Global Overview
Global Overview 57 40 25 Employees Countries Patents globally Granted* (9 Pending Worldwide*) 14 51 12 Test Tests Partner Categories Laboratories 18 * Patents granted are specific to the GeneType portfolio of products
Slide 19: Delivering Revenue and Growth – Q1 FY23
Delivering Revenue and Growth – Q1 FY23 Cash Receipts (A$'000) $6,789 Q1 CASH RECEIPTS CASH BALANCE 145% A$2.06m A$7.9m* Growth half-year ending December on LY 31, 2021 $2,060 GROSS MARGIN GROSS MARGIN $89 Full Year FY21 Full Year FY22 $850 Q1 FY22 Q1 FY23 A$0.9m 44% Strategic & Operational Highligh
Slide 20: Our FOCUS Core '4'
Execute the B2B commercialisation of the geneType multi-risk test Commercialisation of the geneType suite of multi-risk tests Commercialisation of the geneType suite of multi-risk tests Demonstrate clinical validity & clinical utility of geneType tests Our FOCUS Core ‘4’ EasyDNA & Affinity DNA Reven
Slide 21: Our Innovation – Multi-Risk Test
Our Innovation – Multi-Risk Test GeneType can identify patients ’at risk’ before onset and aid in the early detection and treatment. GeneType Risk assessment test for breast cancer has demonstrated improved early stage detection by 18% and saving approx. US$1.4B per annum4 for the US payer GeneType
Slide 22: GeneType Identifies up to 9 Times More Cancer Risk Patients
GeneType Identifies up to 9 Times More Cancer Risk Patients Compared to Existing SoC Models1 The paper, titled “Integrating Personalised Medicine into Preventative Care through Risk Stratification” Published in the Journal of Precision Medicine 1 https://www.thejournalofprecisionmedicine.com/wp-cont
Slide 23: Pathways to Market
Pathways to Market Executing a multi-brand strategy Consumer initiated Direct to Consumer Medical & Payer Testing (DTC) testing (CIT) Business to Business (B2B) with medical supervision with no medical supervision Oncology – GTG [insert revenue structure Expanded Carrier testing & NIPT [insert reven
Slide 24: Pathways to Market – highest priority
Pathways to Market – highest priority Payer coverage is the key driver of revenues for geneType Medical & Payer Business to Coverage from payers in the US will accelerate adoption of Business (B2B) geneType Risk Assessment Tests more widely Revenue Budget Impact Model (BIM) demonstrates significant
Slide 25: Economic Modeling in the US Payer System
Economic Modeling in the US Payer System1 The economic benefit to the payers in the US is US$1.4B per annum $73 69% - 74% 6.8%-9.2% US Payor system overall increase in Supplemental will save per women getting screening frequency patient per year screened 14.8% - 8.8% 57% - 67% Interval Cancers Early
Slide 26: Divisions of Operations
Divisions of Operations NEW Existing divisions Universal Pharmoco- collection test kit Oncology Genetics & Emerging divisions BC, CRC, PC, Taliaz to support Multi Melanoma Companion Test Launch diagnostics Germline CVD testing (Heart Disease) BRCA, Lynch IHD, AF Syndrome and Somatic testing Carrier
Slide 27: DTC - Growth strategy for EasyDNA
DTC - Growth strategy for EasyDNA PHASE 1 PHASE 2 Brand Re-Ignition Revenue and Growth Focus [insert revenue structure and [insert revenue structure and agreement types] Brand Refreshagreement Website types] Refresh Improved Lead Gen New Sales Channels Product list Product list Multi-brand Portfolio
Slide 28: DTC - Growth strategy for EasyDNA
DTC - Growth strategy for EasyDNA 28
Slide 29: Collaborations
Collaborations Professor Bernard Professor Graham Professor John Rosner Colditz Hopper Channing Division of Network Medicine, Deputy Director, Institute for Public Professorial Fellow at the Centre for Brigham and Women’s Hospital and Health. Washington University School Epidemiology and Biostatisti
Slide 30: Collaborations
Collaborations Professor Jon Memorial Sloane Ohio State Emery Kettering Cancer University Professor of Primary Care Cancer Collaborating on a project to Collaborating on a project to Research at the University of investigate modification of risk in BRCA- investigate modification of risk in BRCA- Mel
Slide 31: Snapshot and Achievements last 12 months
Snapshot and Achievements last 12 months GeneType commercialization EasyDNA integration activities Reimbursement activation ✓ Phase 1 commercial release of the geneType ✓ NEW EasyDNA Website ready for launch ✓ Independently developed Budget Impact Multi-Risk test in US Model (BIM) identifies US$1.4
Slide 32: Thank you
Thank you Investor Relations Adrian Mulcahy Market Eye – Automic Group www.linkedin.com/company/genetype-limited M: +61 438 630 422 E: adrian.mulcahy@automicgroup.com.au www.genetype.com 32
Slide 33: Appendices
Appendices 33
Slide 34: Corporate Overview
Corporate Overview Top 50 share registry breakdown BNY Mellon Board & Management Other Dual Listed on the ASX and Nasdaq Financial Information Share price (AUD) as at 25 October 2022 0.3c Other, 25% ADR price (USD) as at 25 October 2022 $1.20 Ord Shares on Issue (M) 9,234 ASX 52-week trading (AUD lo
Slide 35: Financial Overview
Financial Overview • Net cash outflow of A$3.4 million in Q1 FY’22 (compared to Q4 FY’22 inflow of: A$197k) as we continue to grow EasyDNA and Affinity DNA brand sales and develop and commercialize our geneType tests A$’000 30-Sep-22 30-Jun-22 Change • Cash reserves of A$7.9 million at 30 September
Slide 36: Board and Management: Sales and Scientific expertise leading GTG
Board and Management: Sales and Scientific expertise leading GTG Mr. Peter Rubinstein Dr. Lindsay Wakefield Mr Nick Burrows BEc, LLB MBBS B.Comm, FAICD, FCA, Chairman Non – Executive Director FGIA, FTIA, F Fin Non – Executive Director Non – Executive Director Dr. Jerzy “George” Erika Spaeth Simon Mo
Slide 37: Strong Scientific Leadership: Advisory Board
Strong Scientific Leadership: Advisory Board Professor Jon Emery Professor Finlay Macrae AO Ora K. Gordon, M.D. A.Prof Ron Dick MBBCh MA DPhil FRACGP MRCGP MBBS, MD, FRACP, FRCP, AGAF MD, MS, FACMG MBBS, FRACP, FCSANZ, Research & Education Lead, MWGO is Principal Fellow and Regional Medical Director
Slide 38: Our Intellectual Property
Our Intellectual Property 4 Patents granted in the US 9 Patent families pending • Patent No: US 11,257,569, Methods of • Breast cancer risk assessment assessing risk of developing a severe • Methods for assessing risk of developing prostate cancer response to Coronavirus infection • Methods for asse
Slide 39: Defined Terms
Defined Terms Common Complex Diseases (CCP) – A complex disease is caused by the interaction of multiple genes and environmental factors. Complex diseases are also called multifactorial. Examples of common complex diseases include cancer and heart disease. Polygenic risk score - a number associated
Genetic Technologies — Shareholder Meeting (November 2022) on 6ix